Carcinoma in situ of vulva
ICD-10 D07.1 is a billable code used to indicate a diagnosis of carcinoma in situ of vulva.
Carcinoma in situ of the vulva refers to a localized form of cancer where abnormal cells are present in the outer layer of the vulvar skin but have not invaded deeper tissues. This condition is often asymptomatic and may be detected during routine gynecological examinations or through biopsy of suspicious lesions. The most common types of carcinoma in situ affecting the vulva include squamous cell carcinoma in situ and Paget's disease of the vulva. Risk factors for developing carcinoma in situ include human papillomavirus (HPV) infection, smoking, and immunosuppression. Surveillance protocols typically involve regular gynecological examinations, including visual inspections and Pap smears, to monitor for any changes in the vulvar area. If left untreated, carcinoma in situ can progress to invasive cancer, making early detection and intervention critical. Treatment options may include surgical excision, topical chemotherapy, or laser therapy, depending on the extent and characteristics of the lesion.
Detailed pathology reports, biopsy results, and treatment plans.
Routine screenings, management of abnormal findings, and follow-up care.
Ensure accurate documentation of HPV status and any co-existing conditions.
Comprehensive treatment plans, including surgical notes and follow-up care.
Management of vulvar cancer, including surgical interventions and chemotherapy.
Document the rationale for treatment choices and any multidisciplinary approaches.
Used when excising a carcinoma in situ lesion from the vulva.
Surgical notes detailing the procedure and pathology results.
Ensure that the excision is documented as related to carcinoma in situ.
Carcinoma in situ of the vulva is significant because it represents an early stage of cancer that has not yet invaded surrounding tissues. Early detection and treatment can prevent progression to invasive cancer, which has a higher morbidity and mortality rate.
